Foresee Pharma Taps Veteran CCO for Global Pediatric Drug Launch

TAIPEI, Taiwan – July 09, 2026 – In a move signaling a pivotal transition from a research-driven enterprise to a fully-fledged commercial biopharmaceutical company, Foresee Pharmaceuticals has appointed industry veteran Brian J. Groch as its new Chief Commercial Officer. The strategic hire, effective July 1, 2026, positions Groch to spearhead the global launch of FP-001 42 mg, the company's promising new treatment for central precocious puberty (CPP).

This appointment is more than a C-suite shuffle; it represents a critical inflection point for the Taiwan and US-based company. With its innovative FP-001—a six-month, ready-to-use subcutaneous long-acting injectable—nearing regulatory submission, Foresee is gearing up to build its own commercial infrastructure and directly market its products, starting in the United States and Taiwan. The move underscores the company's confidence in its pipeline and its ambition to become a global player in specialty pharmaceuticals.

A Seasoned Navigator for Commercial Waters

To helm this crucial transition, Foresee has brought in a leader with a formidable three-decade track record in the pharmaceutical industry. Brian J. Groch is a seasoned executive renowned for navigating the complex waters of drug commercialization, from market access and pricing strategies to building high-performance sales teams from the ground up.

His extensive resume includes leadership roles that have shaped the commercial success of multiple therapies across various companies. Before joining Foresee, Groch held executive positions at Remi Therapeutics, Shield Therapeutics, and Veru Inc., where as Chief Commercial Officer he was responsible for all sales and marketing activities. His career is marked by a series of high-stakes launches and strategic builds. At Horizon Pharma, he was a key architect of its rare disease division, and at Telesta Therapeutics, he was tasked with developing the entire commercial strategy for a new bladder cancer therapy.

Perhaps most notably, Groch was instrumental in building the commercial organization at Dendreon for the launch of Provenge™, the first-of-its-kind immunotherapy for advanced prostate cancer. This experience—launching a novel product into a competitive market and successfully securing a positive national coverage decision—provides a direct parallel to the challenge and opportunity awaiting him at Foresee. His deep experience, which began with over 13 years in commercial and marketing management at industry giant Merck, gives him a comprehensive understanding of the entire product lifecycle.

"Brian will lead Foresee in building a commercial team to launch the FP-001 for the treatment of CPP patients in the U.S., Taiwan, and potentially other selected countries," said Dr. Ben Chien, Ph.D., Chairman and Chief Executive Officer of Foresee Pharmaceuticals. "We are excited that Foresee will build upon our R&D success and transition into a new phase of building direct commercialization capabilities."

A New Horizon for Children with Precocious Puberty

The first major test of this new commercial engine will be FP-001 42 mg, a potentially transformative treatment for central precocious puberty. CPP is a rare condition where a child’s body begins puberty prematurely, leading to accelerated bone maturation, which can result in reduced adult height. The condition also carries significant psychosocial challenges for affected children and their families.

While treatments exist, they often require frequent injections, creating a substantial burden for young patients. Foresee's FP-001, a formulation of leuprolide mesylate, is designed to address this challenge directly. Developed using the company's proprietary Stabilized Injectable Formulation (SIF) technology, it provides continuous suppression of pubertal hormones for a full six months with a single, ready-to-use subcutaneous injection. This offers a significant improvement in convenience and adherence over therapies that require more frequent dosing.

The clinical foundation for the launch is solid. In December 2025, the Casppian Phase 3 clinical trial for FP-001 successfully met its primary endpoint with high statistical significance (p-value = 0.0005), demonstrating its efficacy in halting pubertal progression. This success paves the way for the company's planned New Drug Application (NDA) submission to the U.S. FDA in the second half of 2026.

From Taipei to the World Stage: A Global Ambition

Foresee’s strategy for FP-001 showcases a carefully orchestrated global roadmap, reflecting the company's evolution from a regional R&D hub to an international commercial entity. While the initial focus is on the lucrative U.S. market, the company is simultaneously pursuing approvals in its home market of Taiwan and other strategic territories, with submissions planned between late 2026 and early 2027.

This global ambition is not new for Foresee. The company's other key product, CAMCEVI for advanced prostate cancer, is already approved and launched in the U.S., Canada, the EU, and other markets, largely through licensing partners. The launch of FP-001, however, marks a strategic shift towards building direct sales capabilities, allowing the company to retain more value and control over its assets.

The successful development of its SIF long-acting injectable platform is the technological backbone of this expansion. Building on the success of CAMCEVI and FP-001, Foresee is already expanding the platform's application into the multi-billion-dollar central nervous system (CNS) market, with two new candidates expected to enter human trials in late 2027. This diversified pipeline, which also includes oral inhibitors for inflammatory and fibrotic diseases, provides a foundation for sustained growth long after the FP-001 launch.

The appointment of Brian J. Groch is the definitive signal that Foresee Pharmaceuticals is ready to capitalize on its years of scientific innovation. By pairing a validated technology platform and a promising late-stage asset with a proven commercial leader, the company is making a clear statement about its readiness to compete on the global pharmaceutical stage.